

OPTIMA HEALTH PLAN

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-800-750-9692. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. Incomplete form will delay authorization process.

This is a group specific benefit

Drug Requested: *(check applicable box below)*

Weight Management Drugs

| | |
|--|--|
| <input type="checkbox"/> Adipex-P® (phentermine HCl) | <input type="checkbox"/> Belviq®/BelviqXR® (lorcaserin) |
| <input type="checkbox"/> Contrave® (naltrexone HCl/bupropion HCl) | <input type="checkbox"/> Qsymia® (phentermine/topiramate ER) |
| <input type="checkbox"/> Xenical® (orlistat) | <input type="checkbox"/> Lomaira™ (phentermine hydrochloride USP) |
| <input type="checkbox"/> Bontril (phendimetrazine) | <input type="checkbox"/> Regimex (benzphetamine) |
| <input type="checkbox"/> diethylpropion | |

DRUG INFORMATION: Complete information below. Authorization process will be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

▪ **All of the above medications are Pregnancy Category X.**

CLINICAL CRITERIA: At least one of the following criteria **MUST** be met to qualify. Current height/weight **MUST** be included. Chart notes/lab results **MUST** be attached to this request or authorization process will be delayed.

Initial Authorization
Belviq®/Belviq XR® - 12 Weeks Only
ALL other medications listed above - 16 Weeks

Height: _____ Current Weight: _____ BMI: _____

Patient has a BMI of 40 or greater

OR

Patient has a BMI of 35 or greater with co-morbid conditions that may include coronary artery disease, hypertension, CHF, diabetes, dyslipidemia, or sleep apnea.

Comorbid Condition(s): _____ ***(chart notes MUST be attached)***

Continued Approval – 6 months
(contingent upon patient continuing to lose weight up to desired BMI)

- Patients on **Belviq /Belviq XR®** therapy should be discontinued if 5% weight loss is not achieved by week 12.
- Patients on **Contrave®** therapy should be discontinued if 5% weight loss is not achieved after 12 weeks of maintenance dosing.
- For patients on **Qsymia®** therapy should be discontinued or dose escalated if 3% weight loss is not achieved after 12 weeks on 7.5mg/46mg dose. Discontinue **Qsymia®** if 5% weight loss is not achieved after 12 weeks on maximum daily dose of 15mg/92mg.

(signature on next page)

****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.****

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.

Patient Name: _____

Member Optima #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

DEA OR NPI #: _____

*Approved by the Pharmacy and Therapeutics Committee: 9/17/2009

REVISED/UPDATED: 10/6/2014; 10/8/2014; 11/6/2014; 11/20/2014; 1/26/2015; 5/22/2015; 12/29/2015; 11/17/2016; 12/31/2016; 2/8/2017; 3/28/2017; 8/20/2017;
3/7/2018